Common name,GPCRdb ID,Reference ligand,Vendors,Species,Assay Type,Activity Type,Activity Relation,Activity Value,p-value (-log),Fold selectivity,Tested GPCRs,Assay Description,Source,Mol weight,Rot Bonds,H don,H acc,LogP,Smiles,DOI
α-ergocryptine,358,,18,Human,Binding,IC50,=,1.95,8.71,-1,21,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"575,3",5,3,6,"2,43",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,-
α-ergocryptine,358,,18,Human,Binding,Ki,=,0.65,9.19,-1,21,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"575,3",5,3,6,"2,43",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,-
α-ergocryptine,358,,18,Human,Binding,pKi,=,9.19,8.04,-1,21,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"575,3",5,3,6,"2,43",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,-
(+)-sulpiride,3703,,66,Human,Binding,AC50,=,803.3,6.09,-1,23,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"341,1",6,2,5,"0,56",CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
(+)-sulpiride,3703,,66,Human,Binding,IC50,=,128.0,6.89,-1,23,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"341,1",6,2,5,"0,56",CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,-
(+)-sulpiride,3703,,66,Human,Binding,IC50,=,205.0,6.69,-1,23,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"341,1",6,2,5,"0,56",CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,-
(+)-sulpiride,3703,,66,Human,Binding,Ki,=,68.0,7.17,-1,23,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"341,1",6,2,5,"0,56",CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,-
(+)-sulpiride,3703,,66,Human,Binding,Ki,=,43.0,7.37,-1,23,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"341,1",6,2,5,"0,56",CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,-
ACEPROMAZINE,150786,,16,Human,Binding,AC50,=,78.5,7.11,-,11,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"326,1",5,0,4,"4,44",CC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2,https://dx.doi.org/10.1038/s41467-023-40064-9
ACETOPHENAZINE,7074,,25,Human,Binding,AC50,=,11.8,7.93,-,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"411,2",7,1,6,"3,49",CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2,https://dx.doi.org/10.1038/s41467-023-40064-9
amiodarone,398,,47,Human,Binding,AC50,=,3146.4,5.5,-4,40,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,645,11,0,4,"6,94",CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
amiodarone,398,,47,Human,Binding,IC50,=,19952.0,4.7,-4,40,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,645,11,0,4,"6,94",CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,-
amiodarone,398,,47,Human,Binding,Ki,=,6651.0,5.18,-4,40,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,645,11,0,4,"6,94",CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,-
amiodarone,398,,47,Human,Binding,pKi,=,5.18,8.29,-4,40,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,645,11,0,4,"6,94",CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,-
amisulpride,400,,72,Human,Binding,AC50,=,15.0,7.82,-2,53,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"369,2",7,2,6,"1,28",CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
amitriptyline,401,,38,Human,Binding,AC50,=,550.0,6.26,-323,51,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"277,2",3,0,1,"4,17",CN(C)CCC=C1c2ccccc2CCc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
amitriptyline,401,,38,Human,Binding,IC50,=,1009.0,6.0,-323,51,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"277,2",3,0,1,"4,17",CN(C)CCC=C1c2ccccc2CCc2ccccc21,-
amitriptyline,401,,38,Human,Binding,Ki,=,336.0,6.47,-323,51,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"277,2",3,0,1,"4,17",CN(C)CCC=C1c2ccccc2CCc2ccccc21,-
AMLODIPINE,41527,,58,Human,Binding,AC50,=,2900.0,5.54,-,24,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"408,1",8,2,7,"2,27",CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,https://dx.doi.org/10.1038/s41467-023-40064-9
AMODIAQUINE,206241,,47,Human,Binding,AC50,=,8900.0,5.05,-,8,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"355,1",6,2,4,"5,18",CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,https://dx.doi.org/10.1038/s41467-023-40064-9
AMOSULALOL,44861,,29,Human,Binding,AC50,=,440.0,6.36,-,12,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"380,1",9,3,6,"1,35",COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
amoxapine,403,,60,Human,Binding,AC50,=,120.0,6.92,-12,42,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"313,1",0,1,4,"3,43",Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,https://dx.doi.org/10.1038/s41467-023-40064-9
amoxapine,403,,60,Human,Binding,IC50,=,200.0,6.7,-12,42,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"313,1",0,1,4,"3,43",Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,-
amoxapine,403,,60,Human,Binding,Ki,=,67.0,7.17,-12,42,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"313,1",0,1,4,"3,43",Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,-
AMSACRINE,167616,,49,Human,Binding,AC50,=,6900.0,5.16,-,15,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"393,1",5,2,5,"4,51",COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,https://dx.doi.org/10.1038/s41467-023-40064-9
apomorphine,445,,20,Human,Binding,AC50,=,1542.7,5.81,-4,29,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"267,1",0,2,3,"2,85",CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,https://dx.doi.org/10.1038/s41467-023-40064-9
APRINDINE,15289,,20,Human,Binding,AC50,=,15000.0,4.82,-,12,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"322,2",8,0,2,"4,39",CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1,https://dx.doi.org/10.1038/s41467-023-40064-9
ARFORMOTEROL,26817,,34,Human,Binding,AC50,=,10999.9,4.96,1,7,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"344,2",9,4,5,"2,22",COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
aripiprazole,470,,70,Human,Binding,AC50,=,23.7,7.62,-1,60,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"447,1",7,1,4,"4,86",O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,https://dx.doi.org/10.1038/s41467-023-40064-9
ASENAPINE,107587,,16,Human,Binding,AC50,=,57.0,7.24,-18,54,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"285,1",0,0,2,"4,26",CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1,https://dx.doi.org/10.1038/s41467-023-40064-9
astemizole,505,,55,Human,Binding,AC50,=,8600.0,5.07,-53,48,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"458,2",8,1,5,"5,35",COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
astemizole,505,,55,Human,Binding,IC50,=,4521.0,5.34,-53,48,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"458,2",8,1,5,"5,35",COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,-
astemizole,505,,55,Human,Binding,Ki,=,1507.0,5.82,-53,48,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"458,2",8,1,5,"5,35",COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,-
astemizole,505,,55,Human,Binding,pKi,=,5.82,8.23,-53,48,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"458,2",8,1,5,"5,35",COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,-
AZATADINE,209982,,33,Human,Binding,AC50,=,7300.0,5.14,-,11,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"290,2",0,0,2,"3,71",CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
BAZEDOXIFENE,178724,,43,Human,Binding,AC50,=,4700.0,5.33,-,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"470,3",7,2,5,"6,33",Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,https://dx.doi.org/10.1038/s41467-023-40064-9
BENIDIPINE,77126,,16,Human,Binding,AC50,=,29999.9,4.52,-,11,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"505,2",7,1,8,"4,21",COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1,https://dx.doi.org/10.1038/s41467-023-40064-9
benperidol,596,,33,Human,Binding,AC50,=,7.7,8.11,1,24,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"381,2",6,1,4,"3,77",O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
benzatropine,597,,17,Human,Binding,AC50,=,17999.9,4.75,-,27,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"307,2",4,0,2,"4,42",CN1[C@H]2CC[C@@H]1C[C@H](OC(c1ccccc1)c1ccccc1)C2,https://dx.doi.org/10.1038/s41467-023-40064-9
BENZETHONIUM,11852,,18,Human,Binding,AC50,=,3794.7,5.42,-,35,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"412,3",11,0,2,"6,07",CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
BENZOTHIAZYL DISULFIDE,189057,,54,Human,Binding,IC50,=,5866.0,5.23,-26,13,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,332,3,0,6,"5,71",c1ccc2sc(SSc3nc4ccccc4s3)nc2c1,-
BENZOTHIAZYL DISULFIDE,189057,,54,Human,Binding,Ki,=,1955.0,5.71,-26,13,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,332,3,0,6,"5,71",c1ccc2sc(SSc3nc4ccccc4s3)nc2c1,-
benzquinamide,599,,30,Human,Binding,AC50,=,2500.0,5.6,-26,9,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"404,2",6,0,6,"2,42",CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O,https://dx.doi.org/10.1038/s41467-023-40064-9
BEPRIDIL,4301,,35,Human,Binding,AC50,=,12999.9,4.89,-,22,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"366,3",10,0,3,"4,83",CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,https://dx.doi.org/10.1038/s41467-023-40064-9
BETAMETHASONE DIPROPIONATE,14419,,30,Human,Binding,AC50,=,770.0,6.11,-,3,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"504,3",6,1,7,"3,82",CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,https://dx.doi.org/10.1038/s41467-023-40064-9
BOPINDOLOL,121354,,36,Human,Binding,AC50,=,6900.0,5.16,-,12,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"380,2",7,2,4,"4,47",Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1,https://dx.doi.org/10.1038/s41467-023-40064-9
BOSUTINIB,100270,,65,Human,Binding,AC50,=,930.0,6.03,-,23,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"529,2",9,1,8,"5,19",COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,https://dx.doi.org/10.1038/s41467-023-40064-9
bromocriptine,729,,28,Human,Binding,AC50,=,27.8,7.56,-6,45,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"653,2",5,3,6,"3,19",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,https://dx.doi.org/10.1038/s41467-023-40064-9
bromocriptine,729,,28,Human,Binding,IC50,=,1.58,8.8,-6,45,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"653,2",5,3,6,"3,19",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,-
bromocriptine,729,,28,Human,Binding,Ki,=,0.53,9.28,-6,45,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"653,2",5,3,6,"3,19",CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,-
BROMPERIDOL,99377,,50,Human,Binding,AC50,=,22.0,7.66,-1,24,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"419,1",6,1,3,"4,54",O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
buspirone,745,,38,Human,Binding,AC50,=,520.0,6.28,-13,34,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"385,2",6,0,6,"2,09",O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
buspirone,745,,38,Human,Binding,IC50,=,323.0,6.49,-13,34,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"385,2",6,0,6,"2,09",O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,-
buspirone,745,,38,Human,Binding,Ki,=,108.0,6.97,-13,34,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"385,2",6,0,6,"2,09",O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,-
BUTRIPTYLINE,78430,,26,Human,Binding,AC50,=,16000.0,4.8,-,10,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"293,2",4,0,1,"4,50",CC(CC1c2ccccc2CCc2ccccc21)CN(C)C,https://dx.doi.org/10.1038/s41467-023-40064-9
cabergoline,778,,41,Human,Binding,AC50,=,13.0,7.89,-1,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"451,3",8,2,4,"3,19",C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,https://dx.doi.org/10.1038/s41467-023-40064-9
carvedilol,803,,59,Human,Binding,AC50,=,130.0,6.89,-38,35,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"406,2",10,3,5,"3,74",COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,https://dx.doi.org/10.1038/s41467-023-40064-9
carvedilol,803,,59,Human,Binding,IC50,=,146.0,6.84,-38,35,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"406,2",10,3,5,"3,74",COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,-
carvedilol,803,,59,Human,Binding,Ki,=,49.0,7.31,-38,35,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"406,2",10,3,5,"3,74",COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,-
carvedilol,803,,59,Human,Binding,pKi,=,7.31,8.14,-38,35,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"406,2",10,3,5,"3,74",COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,-
CEFEPIME,66823,,25,Human,Binding,AC50,=,18999.8,4.72,-,3,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"480,1",7,2,10,"-1,28",CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,https://dx.doi.org/10.1038/s41467-023-40064-9
CEFPROZIL,112658,,8,Human,Binding,AC50,=,25999.8,4.58,-,2,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"389,1",5,4,6,"0,71",CC=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1,https://dx.doi.org/10.1038/s41467-023-40064-9
CHEMBL1221512,15618,,4,Human,Binding,IC50,=,157.0,6.8,-5,8,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"559,3",18,4,9,"1,75",CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS,-
CHEMBL1221512,15618,,4,Human,Binding,Ki,=,52.0,7.28,-5,8,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"559,3",18,4,9,"1,75",CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS,-
CHEMBL141343,32701,,12,Human,Binding,IC50,=,16760.0,4.78,-16,11,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"520,4",5,1,8,"4,21",Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2,-
CHEMBL141343,32701,,12,Human,Binding,Ki,=,5587.0,5.25,-16,11,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"520,4",5,1,8,"4,21",Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2,-
CHEMBL2365712,89164,,10,Human,Binding,AC50,=,53.0,7.28,-,13,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"563,3",4,3,6,"2,13",CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,https://dx.doi.org/10.1038/s41467-023-40064-9
CHEMBL3639415,124463,,0,Human,Binding,Ki,=,486.0,6.31,-53,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"370,2",5,1,5,"3,04",CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3639416,124464,,0,Human,Binding,Ki,=,1935.0,5.71,-104,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,3",7,1,6,"3,33",Cc1cc2c(c(N3CCN(CC[C@H]4CC[C@H](NC(=O)CC5CCOCC5)CC4)CC3)n1)CCO2,-
CHEMBL3642680,124876,,0,Human,Binding,Ki,=,802.0,6.1,-123,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"468,3",8,1,6,"4,22",CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5occc45)CC3)CC2)C1,-
CHEMBL3642681,124877,,0,Human,Binding,Ki,=,1538.0,5.81,-177,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"468,3",7,2,6,"3,96",O=C(C[C@H]1CC[C@H](O)CC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642682,124878,,0,Human,Binding,Ki,=,780.0,6.11,-120,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"384,3",6,1,5,"3,42",CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642683,124879,,0,Human,Binding,Ki,=,1347.0,5.87,-165,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"414,3",8,1,6,"3,05",COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642684,124880,,0,Human,Binding,Ki,=,959.0,6.02,-93,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"400,2",7,2,6,"2,40",O=C(CCO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642685,124881,,0,Human,Binding,Ki,=,1360.0,5.87,-239,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"386,2",6,2,6,"2,01",O=C(CO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642686,124882,,0,Human,Binding,Ki,=,1158.0,5.94,-263,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"400,2",7,1,6,"2,66",COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642687,124883,,0,Human,Binding,Ki,=,1463.0,5.83,-263,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"482,3",8,1,6,"4,61",CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5occc45)CC3)CC2)CC1,-
CHEMBL3642688,124884,,0,Human,Binding,Ki,=,683.0,6.17,-109,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"454,3",7,1,6,"3,83",O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642689,124885,,0,Human,Binding,Ki,=,515.0,6.29,-177,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"440,3",6,1,6,"3,44",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1)C1CCOCC1,-
CHEMBL3642690,124886,,0,Human,Binding,Ki,=,996.0,6.0,-134,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"414,3",8,1,6,"3,05",CCOCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642691,124887,,0,Human,Binding,Ki,=,261.0,6.58,-60,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"396,3",6,1,5,"3,42",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1)C1CC1,-
CHEMBL3642692,124888,,0,Human,Binding,Ki,=,866.0,6.06,-128,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"406,2",6,1,6,"2,45",CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642693,124889,,0,Human,Binding,Ki,=,119.0,6.92,-63,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"386,2",5,1,5,"3,50",CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642694,124890,,0,Human,Binding,Ki,=,780.0,6.11,-91,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"420,2",7,1,6,"2,84",CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642695,124891,,0,Human,Binding,Ki,=,539.0,6.27,-102,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"435,2",7,1,6,"2,29",CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1,-
CHEMBL3642696,124892,,0,Human,Binding,Ki,=,163.0,6.79,-102,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"400,2",6,1,5,"3,89",CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642697,124893,,0,Human,Binding,Ki,=,305.0,6.52,-158,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"430,2",8,1,6,"3,52",COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642698,124894,,0,Human,Binding,Ki,=,302.0,6.52,-120,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"498,3",8,1,6,"5,08",CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)CC1,-
CHEMBL3642699,124895,,0,Human,Binding,Ki,=,271.0,6.57,-79,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"484,3",8,1,6,"4,69",CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)C1,-
CHEMBL3642699,124895,,0,Human,Binding,Ki,=,234.0,6.63,-79,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"484,3",8,1,6,"4,69",CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)C1,-
CHEMBL3642700,124897,,0,Human,Binding,Ki,=,220.0,6.66,-100,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"416,2",7,1,6,"3,13",COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642701,124898,,0,Human,Binding,Ki,=,144.0,6.84,-53,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,3",7,1,6,"4,30",O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642702,124899,,0,Human,Binding,Ki,=,992.0,6.0,-588,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"456,3",6,1,6,"3,91",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1)C1CCOCC1,-
CHEMBL3642703,124900,,0,Human,Binding,Ki,=,246.0,6.61,-81,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"484,3",8,1,6,"4,69",CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)C1,-
CHEMBL3642704,124901,,0,Human,Binding,Ki,=,218.0,6.66,-154,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"402,2",6,2,6,"2,48",O=C(CO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642705,124902,,0,Human,Binding,Ki,=,392.0,6.41,-97,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"484,3",7,2,6,"4,42",O=C(C[C@H]1CC[C@H](O)CC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642706,124903,,0,Human,Binding,Ki,=,461.0,6.34,-87,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"483,3",6,1,6,"4,88",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1)c1ccnc2ccccc12,-
CHEMBL3642707,124904,,0,Human,Binding,Ki,=,265.0,6.58,-91,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"422,2",6,1,6,"2,92",CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642708,124905,,0,Human,Binding,Ki,=,217.0,6.66,-75,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"436,2",7,1,6,"3,31",CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1,-
CHEMBL3642709,124906,,0,Human,Binding,Ki,=,770.1,6.11,-61,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"372,3",5,1,5,"2,22",CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642710,124908,,0,Human,Binding,Ki,=,503.5,6.3,-85,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"442,3",6,1,6,"2,63",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCOCC1,-
CHEMBL3642711,124909,,0,Human,Binding,Ki,=,869.0,6.06,-43,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"456,3",7,1,6,"3,02",O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642712,124910,,0,Human,Binding,Ki,=,1488.0,5.83,-85,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"416,3",8,1,6,"2,24",COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642713,124911,,0,Human,Binding,Ki,=,812.7,6.09,-83,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"386,3",6,1,5,"2,61",CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642714,124912,,0,Human,Binding,Ki,=,1471.4,5.83,-151,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"458,3",7,1,7,"2,01",O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642715,124913,,0,Human,Binding,Ki,=,1545.4,5.81,-141,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"402,3",7,1,6,"1,85",COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642716,124914,,0,Human,Binding,Ki,=,1018.3,5.99,-104,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"450,2",7,1,7,"1,25",CS(=O)(=O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642717,124915,,0,Human,Binding,Ki,=,1568.0,5.8,-128,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"388,2",6,2,6,"1,20",O=C(CO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642718,124916,,0,Human,Binding,Ki,=,733.5,6.13,-64,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"402,3",7,2,6,"1,59",O=C(CCO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642719,124917,,0,Human,Binding,Ki,=,609.5,6.21,-61,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",6,1,6,"2,24",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCOC1,-
CHEMBL3642720,124918,,0,Human,Binding,Ki,=,1044.0,5.98,-165,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",6,1,6,"2,38",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCCO1,-
CHEMBL3642721,124919,,0,Human,Binding,Ki,=,481.2,6.32,-63,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"434,3",6,1,5,"3,52",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccccc1,-
CHEMBL3642722,124920,,0,Human,Binding,Ki,=,341.9,6.47,-31,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"452,3",6,1,5,"3,66",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(F)cc1,-
CHEMBL3642723,124921,,0,Human,Binding,Ki,=,289.2,6.54,-21,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"468,2",6,1,5,"4,17",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(Cl)cc1,-
CHEMBL3642724,124922,,0,Human,Binding,Ki,=,871.2,6.06,-46,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"502,3",6,1,5,"4,54",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(C(F)(F)F)cc1,-
CHEMBL3642725,124923,,0,Human,Binding,Ki,=,1269.5,5.9,-57,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"408,2",6,1,6,"1,64",CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642726,124924,,0,Human,Binding,Ki,=,1093.5,5.96,-61,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"422,2",7,1,6,"2,03",CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642727,124925,,0,Human,Binding,Ki,=,240.0,6.62,-35,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"488,2",7,1,6,"3,21",O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(F)cc1,-
CHEMBL3642728,124926,,0,Human,Binding,Ki,=,586.8,6.23,-114,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"412,3",7,1,5,"3,00",O=C(CC1CC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642729,124927,,0,Human,Binding,Ki,=,555.0,6.26,-54,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"412,3",6,1,5,"3,00",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCC1,-
CHEMBL3642730,124928,,0,Human,Binding,Ki,=,766.8,6.12,-120,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"442,3",6,1,6,"2,63",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCCOC1,-
CHEMBL3642731,124929,,0,Human,Binding,Ki,=,506.5,6.29,-40,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,3",6,2,6,"3,15",C[C@]1(O)CC[C@H](C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)CC1,-
CHEMBL3642732,124930,,0,Human,Binding,Ki,=,475.0,6.32,-77,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,3",6,2,6,"3,15",C[C@]1(O)CC[C@@H](C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)CC1,-
CHEMBL3642733,124931,,0,Human,Binding,Ki,=,5340.0,5.27,-281,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"517,3",7,1,6,"4,51",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCCCC2)cc1,-
CHEMBL3642734,124932,,0,Human,Binding,Ki,=,867.1,6.06,-194,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"519,3",7,1,7,"3,35",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCOCC2)cc1,-
CHEMBL3642735,124933,,0,Human,Binding,Ki,=,592.9,6.23,-100,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"414,3",6,2,6,"1,73",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1(O)CC1,-
CHEMBL3642736,124934,,0,Human,Binding,Ki,=,702.5,6.15,-91,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"397,2",6,1,6,"2,12",N#CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642737,124935,,0,Human,Binding,Ki,=,687.5,6.16,-104,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"440,2",6,1,5,"3,16",O=C(CC(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642738,124936,,0,Human,Binding,Ki,=,1124.0,5.95,-95,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"458,3",7,1,7,"2,01",O=C(C[C@@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642739,124937,,0,Human,Binding,Ki,=,547.5,6.26,-151,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"485,3",6,1,6,"4,07",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccnc2ccccc12,-
CHEMBL3642740,124938,,0,Human,Binding,Ki,=,485.6,6.31,-44,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"398,3",6,1,5,"2,61",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CC1,-
CHEMBL3642741,124939,,0,Human,Binding,Ki,=,1262.8,5.9,-75,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"442,3",7,1,6,"2,77",O=C(CC1CCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642742,124940,,0,Human,Binding,Ki,=,2451.9,5.61,-165,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"484,3",8,1,6,"3,80",CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)CC1,-
CHEMBL3642743,124941,,0,Human,Binding,Ki,=,781.5,6.11,-67,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"437,2",7,1,6,"1,48",CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642744,124942,,0,Human,Binding,Ki,=,1461.0,5.83,-181,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"458,3",7,1,7,"2,01",O=C(C[C@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642745,124943,,0,Human,Binding,Ki,=,914.7,6.04,-63,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"442,3",7,1,6,"2,77",O=C(C[C@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642746,124944,,0,Human,Binding,Ki,=,857.9,6.07,-46,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"442,3",7,1,6,"2,77",O=C(C[C@@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642747,124945,,0,Human,Binding,Ki,=,523.9,6.28,-56,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"414,3",5,1,5,"3,25",CC(C)(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642748,124946,,0,Human,Binding,Ki,=,654.8,6.18,-60,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"414,3",7,1,5,"3,25",CC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642749,124947,,0,Human,Binding,Ki,=,444.2,6.35,-27,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",6,1,5,"3,64",CC(C)(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642750,124948,,0,Human,Binding,Ki,=,602.7,6.22,-67,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"426,3",7,1,5,"3,39",O=C(CC1CCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642751,124949,,0,Human,Binding,Ki,=,438.3,6.36,-25,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"434,2",6,1,5,"2,86",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CC1(F)F,-
CHEMBL3642752,124950,,0,Human,Binding,Ki,=,705.1,6.15,-69,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"400,3",6,1,5,"2,86",CC(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642753,124951,,0,Human,Binding,Ki,=,709.4,6.15,-53,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"414,3",7,1,5,"3,25",CCC(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642754,124952,,0,Human,Binding,Ki,=,754.6,6.12,-69,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",7,1,6,"2,24",O=C(CC1COC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642755,124953,,0,Human,Binding,Ki,=,322.5,6.49,-11,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"401,3",5,1,5,"2,36",CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642756,124954,,0,Human,Binding,Ki,=,773.3,6.11,-40,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"426,2",5,1,5,"2,77",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C(F)(F)F,-
CHEMBL3642757,124955,,0,Human,Binding,Ki,=,198.4,6.7,-12,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"412,3",6,1,5,"3,17",CC(C)=CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642758,124956,,0,Human,Binding,Ki,=,945.4,6.02,-74,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"412,3",7,1,5,"3,17",C/C=C/CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642759,124957,,0,Human,Binding,Ki,=,425.6,6.37,-34,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"396,3",5,1,5,"2,23",CC#CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642760,124958,,0,Human,Binding,Ki,=,837.2,6.08,-35,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"358,2",6,1,5,"1,83",O=CN[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642761,124959,,0,Human,Binding,Ki,=,1304.6,5.88,-331,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"453,3",7,1,7,"2,74",Cc1cc(CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)on1,-
CHEMBL3642762,124960,,0,Human,Binding,Ki,=,396.8,6.4,-25,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"439,3",6,1,7,"2,81",Cc1cc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)on1,-
CHEMBL3642763,124961,,0,Human,Binding,Ki,=,2562.7,5.59,-107,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"457,3",8,1,6,"2,07",CN(C)C(=O)CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642764,124962,,0,Human,Binding,Ki,=,999.7,6.0,-46,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"430,3",7,2,6,"2,37",CC(C)(O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642765,124963,,0,Human,Binding,Ki,=,731.8,6.14,-37,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,3",7,2,6,"2,52",O=C(C[C@@H](O)C(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642766,124964,,0,Human,Binding,Ki,=,887.4,6.05,-44,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"430,3",8,2,6,"2,37",CC[C@H](O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642767,124965,,0,Human,Binding,Ki,=,1291.7,5.89,-66,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,3",8,1,6,"3,41",CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)C1,-
CHEMBL3642768,124966,,0,Human,Binding,Ki,=,926.5,6.03,-66,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"458,3",7,2,7,"1,74",O=C(CC1C[C@H](O)CO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642769,124967,,0,Human,Binding,Ki,=,828.3,6.08,-53,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"400,3",7,1,5,"3,00",CCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642770,124968,,0,Human,Binding,Ki,=,1277.1,5.89,-56,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",8,1,5,"3,64",CC(C)CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642771,124969,,0,Human,Binding,Ki,=,1143.6,5.94,-60,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"414,3",8,1,5,"3,39",CCCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642772,124970,,0,Human,Binding,Ki,=,1253.7,5.9,-63,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"454,3",7,1,5,"3,55",O=C(CCC(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642773,124971,,0,Human,Binding,Ki,=,248.8,6.6,-53,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"384,3",5,1,5,"3,34",CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4occc34)CC2)CC1,-
CHEMBL3642774,124972,,0,Human,Binding,Ki,=,274.6,6.56,-19,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"454,3",6,1,6,"3,75",Cc1cc2occc2c(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4CCOCC4)CC3)CC2)n1,-
CHEMBL3642775,124973,,0,Human,Binding,Ki,=,640.6,6.19,-69,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"468,3",7,1,6,"4,14",Cc1cc2occc2c(N2CCN(CC[C@H]3CC[C@H](NC(=O)CC4CCOCC4)CC3)CC2)n1,-
CHEMBL3642776,124974,,0,Human,Binding,Ki,=,429.7,6.37,-89,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",8,1,6,"3,36",COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4occc34)CC2)CC1,-
CHEMBL3642777,124975,,0,Human,Binding,Ki,=,915.0,6.04,-120,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"386,3",5,1,5,"2,53",CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4c3CCO4)CC2)CC1,-
CHEMBL3642778,124976,,0,Human,Binding,Ki,=,1950.0,5.71,-56,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"456,3",6,1,6,"2,94",Cc1cc2c(c(N3CCN(CC[C@H]4CC[C@H](NC(=O)C5CCOCC5)CC4)CC3)n1)CCO2,-
CHEMBL3642779,124977,,0,Human,Binding,Ki,=,1486.0,5.83,-125,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"430,3",8,1,6,"2,55",COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4c3CCO4)CC2)CC1,-
CHEMBL3642780,124978,,0,Human,Binding,Ki,=,1461.0,5.83,-107,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"384,3",5,1,5,"3,34",CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4occc34)CC2)CC1,-
CHEMBL3642781,124979,,0,Human,Binding,Ki,=,1126.0,5.95,-199,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"454,3",6,1,6,"3,75",Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4CCOCC4)CC3)CC2)c2ccoc12,-
CHEMBL3642782,124980,,0,Human,Binding,Ki,=,2718.0,5.57,-229,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"468,3",7,1,6,"4,14",Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)CC4CCOCC4)CC3)CC2)c2ccoc12,-
CHEMBL3642783,124981,,0,Human,Binding,Ki,=,2471.0,5.61,-204,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",8,1,6,"3,36",COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4occc34)CC2)CC1,-
CHEMBL3642784,124982,,0,Human,Binding,Ki,=,2308.0,5.64,-47,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"386,3",5,1,5,"2,53",CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4c3CCO4)CC2)CC1,-
CHEMBL3642785,124983,,0,Human,Binding,Ki,=,4510.0,5.35,-229,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"456,3",6,1,6,"2,94",Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4CCOCC4)CC3)CC2)c2c1OCC2,-
CHEMBL3642786,124984,,0,Human,Binding,Ki,=,2951.0,5.53,-67,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,3",7,1,6,"3,33",Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)CC4CCOCC4)CC3)CC2)c2c1OCC2,-
CHEMBL3642787,124985,,0,Human,Binding,Ki,=,3564.0,5.45,-95,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"430,3",8,1,6,"2,55",COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4c3CCO4)CC2)CC1,-
CHEMBL3642788,124986,,0,Human,Binding,Ki,=,842.6,6.07,-74,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"456,2",6,2,6,"2,13",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C(O)C(F)(F)F,-
CHEMBL3642789,124987,,0,Human,Binding,Ki,=,1384.9,5.86,-87,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"446,3",9,1,7,"2,21",COC(CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)OC,-
CHEMBL3642790,124988,,0,Human,Binding,Ki,=,2365.4,5.63,-128,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"460,3",10,1,7,"2,60",COC(CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)OC,-
CHEMBL3642791,124989,,0,Human,Binding,Ki,=,516.0,6.29,-53,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"518,2",7,1,8,"2,98",CS(=O)(=O)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)s1,-
CHEMBL3642792,124990,,0,Human,Binding,Ki,=,312.6,6.5,-20,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"449,3",6,1,6,"3,22",Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cn1,-
CHEMBL3642793,124991,,0,Human,Binding,Ki,=,381.2,6.42,-29,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"459,3",6,1,6,"3,39",N#Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cc1,-
CHEMBL3642794,124992,,0,Human,Binding,Ki,=,179.5,6.75,-39,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"532,4",7,1,7,"3,27",CN1CCN(c2ccc(C(=O)N[C@H]3CC[C@H](CCN4CCN(c5nccc6c5CCO6)CC4)CC3)cc2)CC1,-
CHEMBL3642795,124993,,0,Human,Binding,Ki,=,998.4,6.0,-64,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"520,3",7,1,8,"2,75",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCOCC2)nc1,-
CHEMBL3642796,124994,,0,Human,Binding,Ki,=,222.9,6.65,-18,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"511,3",7,1,6,"4,58",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-c2cccnc2)cc1,-
CHEMBL3642797,124995,,0,Human,Binding,Ki,=,3372.0,5.47,-190,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"478,3",6,1,7,"3,25",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc2c(c1)OCO2,-
CHEMBL3642798,124996,,0,Human,Binding,Ki,=,3042.0,5.52,-162,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"492,3",7,1,7,"3,17",O=C(Cc1ccc2c(c1)OCO2)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642799,124997,,0,Human,Binding,Ki,=,958.6,6.02,-97,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"428,3",6,2,6,"2,12",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1(O)CCC1,-
CHEMBL3642800,124998,,0,Human,Binding,Ki,=,1265.0,5.9,-162,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"416,3",6,2,6,"1,97",CC(C)(O)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642801,124999,,0,Human,Binding,Ki,=,116.6,6.93,-8,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"567,3",7,1,8,"2,75",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCS(=O)(=O)CC2)cc1,-
CHEMBL3642802,125000,,0,Human,Binding,Ki,=,478.0,6.32,-13,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"500,3",7,1,7,"3,70",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-n2cccn2)cc1,-
CHEMBL3642803,125001,,0,Human,Binding,Ki,=,2147.0,5.67,-109,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"516,3",7,1,8,"3,88",Cc1nc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCN(c5nccc6c5CCO6)CC4)CC3)c2)no1,-
CHEMBL3642804,125002,,0,Human,Binding,Ki,=,500.6,6.3,-24,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"485,3",6,1,6,"4,07",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc2ncccc2c1,-
CHEMBL3642805,125003,,0,Human,Binding,Ki,=,1308.9,5.88,-89,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"489,3",7,1,7,"3,59",O=C(Cc1noc2ccccc12)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642806,125004,,0,Human,Binding,Ki,=,506.0,6.3,-27,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"521,3",7,1,9,"2,14",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1cnc(N2CCOCC2)cn1,-
CHEMBL3642807,125005,,0,Human,Binding,Ki,=,1663.0,5.78,-25,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"490,3",6,1,5,"4,82",CC(C)(C)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cc1,-
CHEMBL3642808,125006,,0,Human,Binding,Ki,=,518.3,6.29,-23,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"502,2",6,1,5,"4,82",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(Cl)cc1Cl,-
CHEMBL3642809,125007,,0,Human,Binding,Ki,=,163.3,6.79,-6,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"499,3",7,1,6,"4,31",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-n2cccc2)cc1,-
CHEMBL3642810,125008,,0,Human,Binding,Ki,=,1132.0,5.95,-60,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"510,3",7,1,5,"5,18",O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-c2ccccc2)cc1,-
CHEMBL3642811,125009,,0,Human,Binding,Ki,=,680.5,6.17,-95,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"416,3",7,1,6,"2,24",CO[C@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642812,125010,,0,Human,Binding,Ki,=,3161.0,5.5,-75,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"506,3",7,1,6,"4,70",CC(C)(C)Oc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cc1,-
CHEMBL3642813,125011,,0,Human,Binding,Ki,=,788.5,6.1,-39,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"416,3",7,1,6,"2,24",CO[C@@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642814,125012,,0,Human,Binding,Ki,=,242.6,6.62,-15,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"470,2",7,1,6,"3,07",O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccccc1,-
CHEMBL3642815,125013,,0,Human,Binding,Ki,=,801.3,6.1,-26,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"430,3",8,1,6,"2,63",COC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642816,125014,,0,Human,Binding,Ki,=,842.7,6.07,-20,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"430,3",8,2,6,"2,37",CC[C@@H](O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHEMBL3642817,125015,,0,Human,Binding,Ki,=,408.6,6.39,-18,3,"Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.",ChEMBL,"442,3",7,2,6,"2,51",O=C(CC1(O)CCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1,-
CHLORHEXIDINE,207729,,57,Human,Binding,AC50,=,4200.0,5.38,-,27,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"504,2",9,10,4,"4,17",N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
chlorpromazine,919,,48,Human,Binding,AC50,=,52.5,7.28,-2,77,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"318,1",4,0,3,"4,89",CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,https://dx.doi.org/10.1038/s41467-023-40064-9
chlorpromazine,919,,48,Human,Binding,IC50,=,54.0,7.27,-2,77,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"318,1",4,0,3,"4,89",CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,-
chlorpromazine,919,,48,Human,Binding,Ki,=,18.0,7.75,-2,77,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"318,1",4,0,3,"4,89",CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,-
cinacalcet,938,,48,Human,Binding,AC50,=,3600.0,5.44,-,31,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"357,2",6,1,1,"6,14",C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,https://dx.doi.org/10.1038/s41467-023-40064-9
CINITAPRIDE,78202,,29,Human,Binding,AC50,=,38.0,7.42,-,13,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"402,2",7,2,6,"3,13",CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
cinnarizine,940,,51,Human,Binding,AC50,=,15000.0,4.82,-6,28,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"368,2",6,0,2,"5,11",C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
cinnarizine,940,,51,Human,Binding,IC50,=,776.0,6.11,-6,28,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"368,2",6,0,2,"5,11",C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,-
cinnarizine,940,,51,Human,Binding,Ki,=,259.0,6.59,-6,28,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"368,2",6,0,2,"5,11",C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,-
cinnarizine,940,,51,Human,Binding,pKi,=,6.59,8.18,-6,28,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"368,2",6,0,2,"5,11",C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,-
cisapride,944,,25,Human,Binding,AC50,=,450.0,6.35,-31,31,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"465,2",9,2,6,"3,36",COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
cisapride,944,,25,Human,Binding,IC50,=,473.0,6.33,-31,31,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"465,2",9,2,6,"3,36",COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,-
cisapride,944,,25,Human,Binding,Ki,=,158.0,6.8,-31,31,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"465,2",9,2,6,"3,36",COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,-
CLEBOPRIDE,110592,,24,Human,Binding,AC50,=,10.0,8.0,-9,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"373,2",5,2,4,"3,33",COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
clemastine,949,,27,Human,Binding,AC50,=,1200.0,5.92,-66,34,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"343,2",6,0,2,"5,10",CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
clemastine,949,,27,Human,Binding,IC50,=,136.0,6.87,-66,34,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"343,2",6,0,2,"5,10",CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,-
clemastine,949,,27,Human,Binding,Ki,=,45.0,7.35,-66,34,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"343,2",6,0,2,"5,10",CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,-
clemastine,949,,27,Human,Binding,pKi,=,7.35,8.13,-66,34,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"343,2",6,0,2,"5,10",CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,-
CLOFAZIMINE,19387,,54,Human,Binding,AC50,=,8961.0,5.05,-,7,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"472,1",4,1,4,"7,49",CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
clomipramine,954,,43,Human,Binding,AC50,=,390.0,6.41,-7,42,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"314,2",4,0,2,"4,53",CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,https://dx.doi.org/10.1038/s41467-023-40064-9
clomipramine,954,,43,Human,Binding,IC50,=,413.0,6.38,-7,42,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"314,2",4,0,2,"4,53",CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,-
clomipramine,954,,43,Human,Binding,Ki,=,138.0,6.86,-7,42,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"314,2",4,0,2,"4,53",CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,-
CLOTHIAPINE,102785,,36,Human,Binding,AC50,=,200.0,6.7,1,21,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"343,1",0,0,4,"4,13",CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
CLOTRIMAZOLE,4781,,63,Human,Binding,AC50,=,4900.0,5.31,-30,46,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"344,1",4,0,2,"5,38",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,https://dx.doi.org/10.1038/s41467-023-40064-9
CLOTRIMAZOLE,4781,,63,Human,Binding,IC50,=,12186.0,4.91,-30,46,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"344,1",4,0,2,"5,38",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,-
CLOTRIMAZOLE,4781,,63,Human,Binding,Ki,=,4062.0,5.39,-30,46,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"344,1",4,0,2,"5,38",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,-
CLOTRIMAZOLE,4781,,63,Human,Binding,pKi,=,5.39,8.27,-30,46,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"344,1",4,0,2,"5,38",Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,-
clozapine,958,,57,Human,Binding,AC50,=,718.6,6.14,-51,98,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"326,1",0,1,4,"3,72",CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
clozapine,958,,57,Human,Binding,IC50,=,387.0,6.41,-51,98,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"326,1",0,1,4,"3,72",CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,-
clozapine,958,,57,Human,Binding,Ki,=,129.0,6.89,-51,98,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"326,1",0,1,4,"3,72",CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,-
CYCLOBENZAPRINE,206050,,27,Human,Binding,AC50,=,3600.0,5.44,-,17,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"275,2",3,0,1,"4,55",CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
cyproheptadine,1301,,39,Human,Binding,IC50,=,164.0,6.79,-61,53,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"287,2",0,0,1,"4,70",CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,-
cyproheptadine,1301,,39,Human,Binding,Ki,=,55.0,7.26,-61,53,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"287,2",0,0,1,"4,70",CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,-
DACOMITINIB ANHYDROUS,78425,,58,Human,Binding,AC50,=,8000.0,5.1,-,5,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"469,2",7,2,6,"5,16",COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,https://dx.doi.org/10.1038/s41467-023-40064-9
darifenacin,1324,,32,Human,Binding,AC50,=,10999.9,4.96,-,22,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"426,2",7,1,3,"3,96",NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1,https://dx.doi.org/10.1038/s41467-023-40064-9
DAUNORUBICIN,62505,,35,Human,Binding,AC50,=,13769.6,4.86,-,21,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"527,2",4,5,11,"1,03",COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,https://dx.doi.org/10.1038/s41467-023-40064-9
DESIPRAMINE,206863,,31,Human,Binding,AC50,=,8400.0,5.08,-43,31,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"266,2",4,1,2,"3,53",CNCCCN1c2ccccc2CCc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
desloratadine,1389,,72,Human,Binding,AC50,=,1600.0,5.8,-,27,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"310,1",0,1,2,"4,02",Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,https://dx.doi.org/10.1038/s41467-023-40064-9
DIETHYLSTILBESTROL,160344,,54,Human,Binding,IC50,=,13321.0,4.88,-30,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"268,1",4,2,2,"4,83",CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,-
DIETHYLSTILBESTROL,160344,,54,Human,Binding,Ki,=,4440.0,5.35,-30,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"268,1",4,2,2,"4,83",CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,-
DIETHYLSTILBESTROL,160344,,54,Human,Binding,pKi,=,5.35,8.27,-30,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"268,1",4,2,2,"4,83",CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,-
DIHYDROERGOCRISTINE,203402,,16,Human,Binding,IC50,=,1.47,8.83,-5,22,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"611,3",5,3,6,"2,72",CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,-
DIHYDROERGOCRISTINE,203402,,16,Human,Binding,Ki,=,0.49,9.31,-5,22,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"611,3",5,3,6,"2,72",CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,-
DIHYDROERGOCRISTINE,203402,,16,Human,Binding,pKi,=,9.31,8.03,-5,22,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"611,3",5,3,6,"2,72",CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,-
dihydroergotamine,1420,,13,Human,Binding,AC50,=,40.0,7.4,-30,42,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"583,3",4,3,6,"2,08",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,https://dx.doi.org/10.1038/s41467-023-40064-9
dihydroergotamine,1420,,13,Human,Binding,IC50,=,8.88,8.05,-30,42,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"583,3",4,3,6,"2,08",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,-
dihydroergotamine,1420,,13,Human,Binding,Ki,=,2.96,8.53,-30,42,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"583,3",4,3,6,"2,08",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,-
dihydroergotamine,1420,,13,Human,Binding,pKi,=,8.53,8.07,-30,42,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"583,3",4,3,6,"2,08",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,-
diphenidol,1433,,30,Human,Binding,IC50,=,3290.0,5.48,-1,14,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"309,2",6,1,2,"4,19",OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,-
diphenidol,1433,,30,Human,Binding,Ki,=,1097.0,5.96,-1,14,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"309,2",6,1,2,"4,19",OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,-
diphenidol,1433,,30,Human,Binding,pKi,=,5.96,8.22,-1,14,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"309,2",6,1,2,"4,19",OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,-
DISULFIRAM,210300,,60,Human,Binding,IC50,=,23018.0,4.64,-5,24,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"296,1",4,0,4,"3,62",CCN(CC)C(=S)SSC(=S)N(CC)CC,-
DISULFIRAM,210300,,60,Human,Binding,Ki,=,7673.0,5.12,-5,24,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"296,1",4,0,4,"3,62",CCN(CC)C(=S)SSC(=S)N(CC)CC,-
DISULFIRAM,210300,,60,Human,Binding,pKi,=,5.12,8.29,-5,24,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"296,1",4,0,4,"3,62",CCN(CC)C(=S)SSC(=S)N(CC)CC,-
dobutamine,1454,,27,Human,Binding,AC50,=,8199.9,5.09,-,17,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"301,2",7,4,4,"2,96",CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
DOMIPHEN,12618,,11,Human,Binding,AC50,=,2000.0,5.7,-,26,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"334,3",15,0,1,"6,06",CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
domperidone,1462,,65,Human,Binding,AC50,=,6.0,8.22,-2,33,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"425,2",5,2,5,"3,35",O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
domperidone,1462,,65,Human,Binding,IC50,=,2.65,8.58,-2,33,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"425,2",5,2,5,"3,35",O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,-
domperidone,1462,,65,Human,Binding,Ki,=,0.88,9.05,-2,33,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"425,2",5,2,5,"3,35",O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,-
DOTHIEPIN,41735,,12,Human,Binding,AC50,=,14000.1,4.85,-,18,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"295,1",3,0,2,"4,68",CN(C)CC/C=C1\c2ccccc2CSc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
DOXEPIN,56283,,21,Human,Binding,AC50,=,1400.0,5.85,-,28,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"279,2",3,0,2,"3,96",CN(C)CCC=C1c2ccccc2COc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
DROPERIDOL,9264,,62,Human,Binding,IC50,=,2.41,8.62,-1,21,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"379,2",6,1,4,"3,68",O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,-
DROPERIDOL,9264,,62,Human,Binding,Ki,=,0.8,9.1,-1,21,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"379,2",6,1,4,"3,68",O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,-
duloxetine,1508,,46,Human,Binding,AC50,=,6599.9,5.18,-97,44,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"297,1",6,1,3,"4,63",CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,https://dx.doi.org/10.1038/s41467-023-40064-9
EBASTINE,102913,,65,Human,Binding,AC50,=,3900.0,5.41,-74,33,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"469,3",9,0,3,"7,22",CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
EBASTINE,102913,,65,Human,Binding,IC50,=,1149.1,5.94,-74,33,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"469,3",9,0,3,"7,22",CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,-
EBASTINE,102913,,65,Human,Binding,Ki,=,383.0,6.42,-74,33,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"469,3",9,0,3,"7,22",CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,-
ECONAZOLE,207971,,50,Human,Binding,IC50,=,12807.0,4.89,-30,38,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,380,6,0,3,"5,80",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,-
ECONAZOLE,207971,,50,Human,Binding,Ki,=,4269.0,5.37,-30,38,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,380,6,0,3,"5,80",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,-
ECONAZOLE,207971,,50,Human,Binding,pKi,=,5.37,8.27,-30,38,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,380,6,0,3,"5,80",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,-
EMETINE,188904,,34,Human,Binding,AC50,=,16000.0,4.8,-,12,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"480,3",7,1,6,"4,94",CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21,https://dx.doi.org/10.1038/s41467-023-40064-9
EPALRESTAT,198942,,55,Human,Binding,AC50,=,9100.0,5.04,-,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,319,4,1,4,"2,92",CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
ERGOCORNINE,29624,,14,Human,Binding,IC50,=,5.03,8.3,-2,18,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"561,3",4,3,6,"2,04",CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,-
ERGOCORNINE,29624,,14,Human,Binding,Ki,=,1.68,8.78,-2,18,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"561,3",4,3,6,"2,04",CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,-
ergometrine,1581,,13,Human,Binding,IC50,=,552.0,6.26,-288,17,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"325,2",3,3,3,"1,53",C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,-
ergometrine,1581,,13,Human,Binding,Ki,=,184.0,6.74,-288,17,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"325,2",3,3,3,"1,53",C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,-
ergotamine,1582,,6,Human,Binding,AC50,=,2200.0,5.66,-15,32,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"581,3",4,3,6,"1,99",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,https://dx.doi.org/10.1038/s41467-023-40064-9
ergotamine,1582,,6,Human,Binding,IC50,=,4.3,8.37,-15,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"581,3",4,3,6,"1,99",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,-
ergotamine,1582,,6,Human,Binding,Ki,=,1.43,8.84,-15,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"581,3",4,3,6,"1,99",CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,-
ERGOTAMINE,218443,,0,Human,Binding,pKi,=,8.85,8.05,-4168,62,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"581,3",4,3,6,"1,99",CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)CC21,-
fenoldopam,1628,,36,Human,Binding,AC50,=,3800.0,5.42,-24,18,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"305,1",1,4,4,"2,73",Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
flunarizine,1657,,39,Human,Binding,IC50,=,352.0,6.45,-5,28,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"404,2",6,0,2,"5,38",Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,-
flunarizine,1657,,39,Human,Binding,Ki,=,117.0,6.93,-5,28,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"404,2",6,0,2,"5,38",Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,-
flunarizine,1657,,39,Human,Binding,pKi,=,6.93,8.16,-5,28,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"404,2",6,0,2,"5,38",Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,-
fluoxetine,1658,,52,Human,Binding,AC50,=,7056.9,5.15,-1862,44,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"309,1",6,1,2,"4,43",CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
fluphenazine,1662,,37,Human,Binding,AC50,=,3.8,8.42,-1,69,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"437,2",6,1,5,"4,31",OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
fluphenazine,1662,,37,Human,Binding,IC50,=,1.62,8.79,-1,69,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"437,2",6,1,5,"4,31",OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,-
fluphenazine,1662,,37,Human,Binding,Ki,=,0.54,9.27,-1,69,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"437,2",6,1,5,"4,31",OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,-
fluspirilene,1664,,37,Human,Binding,AC50,=,43.0,7.37,-1,48,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"475,2",7,1,3,"5,30",O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2,https://dx.doi.org/10.1038/s41467-023-40064-9
GALLOPAMIL,189330,,32,Human,Binding,AC50,=,10000.0,5.0,-,10,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"484,3",14,0,7,"5,10",COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
haloperidol,1911,,63,Human,Binding,AC50,=,12.2,7.91,-1,93,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"375,1",6,1,3,"4,43",O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
haloperidol,1911,,63,Human,Binding,IC50,=,6.59,8.18,-1,93,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"375,1",6,1,3,"4,43",O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,-
haloperidol,1911,,63,Human,Binding,Ki,=,2.2,8.66,-1,93,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"375,1",6,1,3,"4,43",O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,-
HEXAMETHYL PARAROSANILINE,176253,,16,Human,Binding,IC50,=,3178.0,5.5,-2,25,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"372,2",4,0,2,"4,46",CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1,-
HEXAMETHYL PARAROSANILINE,176253,,16,Human,Binding,Ki,=,1059.0,5.97,-2,25,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"372,2",4,0,2,"4,46",CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1,-
HEXAMETHYL PARAROSANILINE,176253,,16,Human,Binding,pKi,=,5.97,8.22,-2,25,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"372,2",4,0,2,"4,46",CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1,-
hydroxyzine,1957,,46,Human,Binding,AC50,=,2400.0,5.62,-5,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"374,2",8,1,4,"3,06",OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
IBOPAMINE,103167,,14,Human,Binding,AC50,=,28000.1,4.55,-,7,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"307,2",7,1,5,"2,57",CNCCc1ccc(OC(=O)C(C)C)c(OC(=O)C(C)C)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
IDARUBICIN,9427,,34,Human,Binding,AC50,=,10999.9,4.96,-,13,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"497,2",3,5,10,"1,02",CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,https://dx.doi.org/10.1038/s41467-023-40064-9
IFENPRODIL,102826,,36,Human,Binding,AC50,=,2700.0,5.57,-,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"325,2",5,2,3,"3,77",CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
iloperidone,2006,,61,Human,Binding,AC50,=,45.4,7.34,-7,48,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"426,2",8,0,6,"4,83",COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
imipramine,2013,,42,Human,Binding,AC50,=,1300.0,5.89,-20,44,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"280,2",4,0,2,"3,88",CN(C)CCCN1c2ccccc2CCc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
INDOCYANINE GREEN ACID FORM,14499,,5,Human,Binding,AC50,=,8799.9,5.06,-,25,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"752,3",14,1,6,"8,71",CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21,https://dx.doi.org/10.1038/s41467-023-40064-9
IPRINDOLE,17999,,26,Human,Binding,AC50,=,6200.0,5.21,-,25,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"284,2",4,0,2,"4,25",CN(C)CCCn1c2c(c3ccccc31)CCCCCC2,https://dx.doi.org/10.1038/s41467-023-40064-9
ISOCONAZOLE,50314,,27,Human,Binding,AC50,=,8900.0,5.05,-,5,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,414,6,0,3,"6,46",Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
ITOPRIDE,78319,,35,Human,Binding,AC50,=,9600.0,5.02,-,3,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"358,2",9,1,5,"2,57",COc1ccc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
ketanserin,2181,,61,Human,Binding,AC50,=,2500.0,5.6,-177,56,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"395,2",5,1,5,"2,42",O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
LASOFOXIFENE,111644,,40,Human,Binding,AC50,=,8600.0,5.07,-,23,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"413,2",6,1,3,"5,73",Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
LIDAMIDINE,172649,,27,Human,Binding,AC50,=,1600.0,5.8,-,3,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"220,1",1,3,2,"1,37",CN=C(N)NC(=O)Nc1c(C)cccc1C,https://dx.doi.org/10.1038/s41467-023-40064-9
LIDOFLAZINE,209699,,30,Human,Binding,AC50,=,1500.0,5.82,-,18,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"491,3",9,1,3,"5,75",Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
lisuride,2325,,21,Human,Binding,IC50,=,2.86,8.54,-2,44,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"338,2",3,2,2,"2,84",CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,-
lisuride,2325,,21,Human,Binding,Ki,=,0.95,9.02,-2,44,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"338,2",3,2,2,"2,84",CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,-
LOFEPRAMINE,208853,,39,Human,Binding,AC50,=,18999.8,4.72,-15,25,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"418,2",7,0,3,"5,78",CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
LOMERIZINE,100668,,35,Human,Binding,AC50,=,7000.0,5.16,-,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"468,2",8,0,5,"4,90",COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
LONAZOLAC,23640,,36,Human,Binding,AC50,=,830.0,6.08,-,1,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"312,1",4,1,3,"3,82",O=C(O)Cc1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
loxapine,2348,,42,Human,Binding,AC50,=,58.3,7.23,-4,52,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"327,1",0,0,4,"3,77",CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
lurasidone,2385,,44,Human,Binding,AC50,=,18.0,7.75,-2,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"492,3",5,0,6,"4,26",O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
MADURAMICIN,67820,,12,Human,Binding,IC50,=,702.0,6.15,-295,15,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"916,5",13,4,16,"4,32",CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC,-
MADURAMICIN,67820,,12,Human,Binding,Ki,=,234.0,6.63,-295,15,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"916,5",13,4,16,"4,32",CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC,-
MANIDIPINE 6300,7228,,58,Human,Binding,AC50,=,6599.9,5.18,-,6,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"610,3",10,1,9,"4,95",COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1,https://dx.doi.org/10.1038/s41467-023-40064-9
MAPROTILINE,82440,,34,Human,Binding,AC50,=,12999.9,4.89,-128,29,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"277,2",4,1,1,"4,21",CNCCCC12CCC(c3ccccc31)c1ccccc12,https://dx.doi.org/10.1038/s41467-023-40064-9
MAPROTILINE,82440,,34,Human,Binding,IC50,=,3463.0,5.46,-128,29,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"277,2",4,1,1,"4,21",CNCCCC12CCC(c3ccccc31)c1ccccc12,-
MAPROTILINE,82440,,34,Human,Binding,Ki,=,1154.0,5.94,-128,29,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"277,2",4,1,1,"4,21",CNCCCC12CCC(c3ccccc31)c1ccccc12,-
MASOPROCOL,106495,,32,Human,Binding,AC50,=,6900.0,5.16,-,14,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"302,2",5,4,4,"3,57",C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
MASOPROCOL,106495,,32,Human,Binding,AC50,=,10000.0,5.0,-,14,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"302,2",5,4,4,"3,57",C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
MEBEVERINE,99367,,27,Human,Binding,AC50,=,21000.0,4.68,-,13,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"429,3",13,0,6,"4,60",CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
MECLIZINE,55838,,37,Human,Binding,AC50,=,3100.0,5.51,-,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"390,2",5,0,2,"5,56",Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
MELITRACEN,9159,,27,Human,Binding,AC50,=,5400.0,5.27,-,21,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"291,2",3,0,1,"4,71",CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
MEQUITAZINE,207084,,54,Human,Binding,AC50,=,8600.0,5.07,-,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"322,1",2,0,3,"4,63",c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2,https://dx.doi.org/10.1038/s41467-023-40064-9
metergoline,2496,,39,Human,Binding,IC50,=,63.0,7.2,-23,49,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"403,2",4,1,4,"4,07",CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21,-
metergoline,2496,,39,Human,Binding,Ki,=,21.0,7.68,-23,49,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"403,2",4,1,4,"4,07",CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21,-
metergoline,2496,,39,Human,Binding,pKi,=,7.68,8.11,-23,49,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"403,2",4,1,4,"4,07",CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21,-
methylergonovine,2509,,14,Human,Binding,IC50,=,829.0,6.08,-31,20,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"339,2",4,3,3,"1,93",CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,-
methylergonovine,2509,,14,Human,Binding,Ki,=,276.0,6.56,-31,20,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"339,2",4,3,3,"1,93",CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,-
methylergonovine,2509,,14,Human,Binding,pKi,=,6.56,8.18,-31,20,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"339,2",4,3,3,"1,93",CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,-
methysergide,2514,,19,Human,Binding,AC50,=,310.0,6.51,-223,69,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"353,2",4,2,4,"1,94",CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1,https://dx.doi.org/10.1038/s41467-023-40064-9
methysergide,2514,,19,Human,Binding,IC50,=,807.0,6.09,-223,69,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"353,2",4,2,4,"1,94",CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1,-
methysergide,2514,,19,Human,Binding,Ki,=,269.0,6.57,-223,69,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"353,2",4,2,4,"1,94",CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1,-
methysergide,2514,,19,Human,Binding,pKi,=,6.57,8.18,-223,69,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"353,2",4,2,4,"1,94",CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1,-
metoclopramide,2518,,51,Human,Binding,AC50,=,110.0,6.96,-2,27,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"299,1",7,2,4,"2,00",CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
metoclopramide,2518,,51,Human,Binding,IC50,=,127.0,6.9,-2,27,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"299,1",7,2,4,"2,00",CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,-
metoclopramide,2518,,51,Human,Binding,Ki,=,42.0,7.38,-2,27,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"299,1",7,2,4,"2,00",CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,-
mianserin,2532,,33,Human,Binding,AC50,=,3200.0,5.5,-316,63,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"264,2",0,0,2,"3,08",CN1CCN2c3ccccc3Cc3ccccc3C2C1,https://dx.doi.org/10.1038/s41467-023-40064-9
MICONAZOLE,209380,,58,Human,Binding,IC50,=,12504.0,4.9,-29,36,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,414,6,0,3,"6,46",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,-
MICONAZOLE,209380,,58,Human,Binding,Ki,=,4168.0,5.38,-29,36,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,414,6,0,3,"6,46",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,-
MICONAZOLE,209380,,58,Human,Binding,pKi,=,5.38,8.27,-29,36,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,414,6,0,3,"6,46",Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,-
molindone,2590,,33,Human,Binding,AC50,=,209.4,6.68,-3,31,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"276,2",3,1,3,"1,96",CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,https://dx.doi.org/10.1038/s41467-023-40064-9
NAFAMOSTAT,98126,,43,Human,Binding,AC50,=,20000.0,4.7,-,15,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"347,1",4,5,4,"2,65",N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
NAFTIFINE,205329,,22,Human,Binding,AC50,=,3900.0,5.41,-,6,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"287,2",5,0,1,"4,99",CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12,https://dx.doi.org/10.1038/s41467-023-40064-9
NAFTOPIDIL,34231,,58,Human,Binding,AC50,=,1000.0,6.0,-,21,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"392,2",7,1,5,"3,41",COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
nebivolol,2757,,41,Human,Binding,AC50,=,3500.0,5.46,-,24,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"405,2",6,3,5,"2,36",OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,https://dx.doi.org/10.1038/s41467-023-40064-9
nefazodone,2759,,31,Human,Binding,AC50,=,270.0,6.57,-20,40,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"469,2",10,0,7,"3,55",CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
nemonapride,2762,,13,Human,Binding,AC50,=,0.3,9.52,-3,31,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"387,2",6,2,4,"3,78",CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl,https://dx.doi.org/10.1038/s41467-023-40064-9
NERATINIB,63562,,59,Human,Binding,AC50,=,9900.1,5.0,-,6,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"556,2",11,2,8,"5,93",CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,https://dx.doi.org/10.1038/s41467-023-40064-9
NITAZOXANIDE,31229,,62,Human,Binding,AC50,=,14000.1,4.85,-,32,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,307,4,1,7,"2,23",CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,https://dx.doi.org/10.1038/s41467-023-40064-9
NITRACRINE,96601,,25,Human,Binding,AC50,=,14000.1,4.85,-,13,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"324,2",6,1,5,"3,66",CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12,https://dx.doi.org/10.1038/s41467-023-40064-9
NITROXOLINE,37419,,62,Human,Binding,AC50,=,6400.0,5.19,-,10,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,190,1,1,4,"1,85",O=[N+]([O-])c1ccc(O)c2ncccc12,https://dx.doi.org/10.1038/s41467-023-40064-9
nortriptyline,2866,,32,Human,Binding,AC50,=,5699.9,5.24,-17,35,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"263,2",3,1,1,"3,83",CNCCC=C1c2ccccc2CCc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
olanzapine,2914,,65,Human,Binding,AC50,=,71.0,7.15,-10,67,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"312,1",1,1,5,"1,75",Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
olanzapine,2914,,65,Human,Binding,IC50,=,118.0,6.93,-10,67,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"312,1",1,1,5,"1,75",Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1,-
olanzapine,2914,,65,Human,Binding,Ki,=,39.0,7.41,-10,67,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"312,1",1,1,5,"1,75",Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1,-
OPIPRAMOL,133581,,40,Human,Binding,AC50,=,884.6,6.05,-,15,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"363,2",6,1,4,"3,31",OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
OSIMERTINIB,115628,,61,Human,Binding,AC50,=,7100.0,5.15,-,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"499,3",10,2,8,"4,51",C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,https://dx.doi.org/10.1038/s41467-023-40064-9
OTILONIUM,35070,,5,Human,Binding,AC50,=,4300.0,5.37,-,28,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"483,3",16,1,4,"6,32",CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
OXAPROZIN,5393,,62,Human,Binding,AC50,=,1180.0,5.93,-,10,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"293,1",5,1,3,"4,03",O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,https://dx.doi.org/10.1038/s41467-023-40064-9
OXATOMIDE,29284,,49,Human,Binding,AC50,=,330.0,6.48,-,20,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"426,2",7,1,4,"4,13",O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
OXYPERTINE,78295,,23,Human,Binding,AC50,=,920.0,6.04,-,11,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"379,2",6,1,4,"3,86",COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
pasireotide,3007,,26,Human,Binding,AC50,=,3800.0,5.42,-,22,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,-,-,-,-,-,-,https://dx.doi.org/10.1038/s41467-023-40064-9
pergolide,3054,,28,Human,Binding,AC50,=,110.3,6.96,-26,38,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"314,2",4,1,2,"4,27",CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,https://dx.doi.org/10.1038/s41467-023-40064-9
pergolide,3054,,28,Human,Binding,IC50,=,111.0,6.96,-26,38,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"314,2",4,1,2,"4,27",CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,-
pergolide,3054,,28,Human,Binding,Ki,=,37.0,7.43,-26,38,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"314,2",4,1,2,"4,27",CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,-
perphenazine,3057,,57,Human,Binding,AC50,=,17.0,7.77,-1,38,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"403,1",6,1,5,"3,94",OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
PHENAZOPYRIDINE,16656,,34,Human,Binding,AC50,=,3300.0,5.48,-,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"213,1",2,2,5,"2,66",Nc1ccc(/N=N/c2ccccc2)c(N)n1,https://dx.doi.org/10.1038/s41467-023-40064-9
phenoxybenzamine,3095,,24,Human,Binding,AC50,=,5000.0,5.3,-,25,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"303,1",8,0,2,"4,20",CC(COc1ccccc1)N(CCCl)Cc1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
pimozide,3125,,49,Human,Binding,AC50,=,16.0,7.8,-11,53,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"461,2",7,1,3,"5,86",O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
PIPAMAZINE,67821,,11,Human,Binding,IC50,=,4.05,8.39,-1,18,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"401,1",5,1,4,"4,53",NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,-
PIPAMAZINE,67821,,11,Human,Binding,Ki,=,1.35,8.87,-1,18,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"401,1",5,1,4,"4,53",NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,-
PIPAMAZINE,67821,,11,Human,Binding,pKi,=,8.87,8.05,-1,18,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"401,1",5,1,4,"4,53",NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,-
PIPERACETAZINE,51685,,37,Human,Binding,AC50,=,13.0,7.89,-,15,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"410,2",7,1,5,"4,98",CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2,https://dx.doi.org/10.1038/s41467-023-40064-9
PIRENOXINE,27995,,38,Human,Binding,AC50,=,9499.9,5.02,-,10,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,308,1,2,6,"2,25",O=C(O)c1cc(O)c2c3nc4ccccc4oc-3cc(=O)c2n1,https://dx.doi.org/10.1038/s41467-023-40064-9
piribedil,3132,,63,Human,Binding,AC50,=,5479.0,5.26,-1,23,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"298,1",3,0,6,"1,53",c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1,https://dx.doi.org/10.1038/s41467-023-40064-9
pizotifen,3134,,58,Human,Binding,AC50,=,210.0,6.68,-1,24,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"295,1",0,0,2,"4,37",CN1CCC(=C2c3ccccc3CCc3sccc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
PONATINIB,10802,,64,Human,Binding,AC50,=,15000.0,4.82,-,20,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"532,2",4,1,6,"4,46",Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,https://dx.doi.org/10.1038/s41467-023-40064-9
pramipexole,3159,,58,Human,Binding,AC50,=,14000.1,4.85,-63,41,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"211,1",3,2,4,"1,58",CCCN[C@H]1CCc2nc(N)sc2C1,https://dx.doi.org/10.1038/s41467-023-40064-9
PRENYLAMINE,91619,,25,Human,Binding,AC50,=,2900.0,5.54,-,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"329,2",8,1,1,"5,43",CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
prochlorperazine,3173,,38,Human,Binding,AC50,=,44.0,7.36,1,44,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"373,1",4,0,4,"4,58",CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
prochlorperazine,3173,,38,Human,Binding,IC50,=,11.0,7.96,1,44,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"373,1",4,0,4,"4,58",CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,-
prochlorperazine,3173,,38,Human,Binding,Ki,=,3.61,8.44,1,44,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"373,1",4,0,4,"4,58",CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,-
promazine,3182,,26,Human,Binding,AC50,=,400.0,6.4,-41,37,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"284,1",4,0,3,"4,24",CN(C)CCCN1c2ccccc2Sc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
promazine,3182,,26,Human,Binding,IC50,=,505.0,6.3,-41,37,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"284,1",4,0,3,"4,24",CN(C)CCCN1c2ccccc2Sc2ccccc21,-
promazine,3182,,26,Human,Binding,Ki,=,168.0,6.78,-41,37,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"284,1",4,0,3,"4,24",CN(C)CCCN1c2ccccc2Sc2ccccc21,-
promethazine,3183,,36,Human,Binding,AC50,=,1040.0,5.98,-18,35,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"284,1",3,0,3,"4,24",CC(CN1c2ccccc2Sc2ccccc21)N(C)C,https://dx.doi.org/10.1038/s41467-023-40064-9
promethazine,3183,,36,Human,Binding,IC50,=,779.0,6.11,-18,35,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"284,1",3,0,3,"4,24",CC(CN1c2ccccc2Sc2ccccc21)N(C)C,-
promethazine,3183,,36,Human,Binding,Ki,=,260.0,6.58,-18,35,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"284,1",3,0,3,"4,24",CC(CN1c2ccccc2Sc2ccccc21)N(C)C,-
PROPIOMAZINE,14476,,26,Human,Binding,AC50,=,2600.0,5.58,-,15,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"340,2",5,0,4,"4,83",CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2,https://dx.doi.org/10.1038/s41467-023-40064-9
PROTRIPTYLINE,206037,,20,Human,Binding,AC50,=,5200.0,5.28,-,19,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"263,2",4,1,1,"4,30",CNCCCC1c2ccccc2C=Cc2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
PYRVINIUM,14498,,13,Human,Binding,AC50,=,10000.0,5.0,-,25,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"382,2",4,0,2,"5,31",Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
quetiapine,3256,,51,Human,Binding,AC50,=,710.0,6.15,-28,64,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"383,2",5,1,6,"2,86",OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
quetiapine,3256,,51,Human,Binding,IC50,=,1329.9,5.88,-28,64,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"383,2",5,1,6,"2,86",OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,-
quetiapine,3256,,51,Human,Binding,Ki,=,443.3,6.35,-28,64,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"383,2",5,1,6,"2,86",OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,-
QUINAGOLIDE,84404,,3,Human,Binding,AC50,=,15.2,7.82,-,11,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"395,2",7,2,4,"2,14",CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21,https://dx.doi.org/10.1038/s41467-023-40064-9
QUINIDINE,19421,,48,Human,Binding,AC50,=,10000.0,5.0,-,11,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"324,2",4,1,4,"3,17",C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,https://dx.doi.org/10.1038/s41467-023-40064-9
raloxifene,3286,,44,Human,Binding,AC50,=,950.0,6.02,-7,29,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"473,2",7,2,6,"6,08",O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,https://dx.doi.org/10.1038/s41467-023-40064-9
raloxifene,3286,,44,Human,Binding,IC50,=,1174.0,5.93,-7,29,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"473,2",7,2,6,"6,08",O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,-
raloxifene,3286,,44,Human,Binding,Ki,=,391.0,6.41,-7,29,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"473,2",7,2,6,"6,08",O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,-
raloxifene,3286,,44,Human,Binding,pKi,=,6.41,8.19,-7,29,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"473,2",7,2,6,"6,08",O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,-
REMOXIPRIDE,84687,,24,Human,Binding,AC50,=,1161.9,5.93,-1,26,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"370,1",6,1,4,"2,68",CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
RIFAMPIN,137055,,20,Human,Binding,AC50,=,9200.0,5.04,-,28,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"822,4",4,6,15,"4,33",CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,https://dx.doi.org/10.1038/s41467-023-40064-9
risperidone,3331,,72,Human,Binding,AC50,=,20.8,7.68,-7,71,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"410,2",4,0,6,"3,59",Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,https://dx.doi.org/10.1038/s41467-023-40064-9
risperidone,3331,,72,Human,Binding,IC50,=,20.0,7.7,-7,71,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"410,2",4,0,6,"3,59",Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,-
risperidone,3331,,72,Human,Binding,Ki,=,6.54,8.18,-7,71,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"410,2",4,0,6,"3,59",Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,-
ropinirole,3370,,38,Human,Binding,AC50,=,7999.4,5.1,-3,33,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"260,2",7,1,2,"3,50",CCCN(CCC)CCc1cccc2c1CC(O)=N2,https://dx.doi.org/10.1038/s41467-023-40064-9
rotigotine,3372,,50,Human,Binding,AC50,=,121.6,6.92,5,21,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"315,2",6,1,3,"4,27",CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,https://dx.doi.org/10.1038/s41467-023-40064-9
salmeterol,3463,,53,Human,Binding,AC50,=,7200.0,5.14,-100,27,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"415,3",16,4,5,"4,11",OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,https://dx.doi.org/10.1038/s41467-023-40064-9
SAQUINAVIR,9838,,41,Human,Binding,AC50,=,10000.0,5.0,-,11,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"670,4",12,5,7,"3,09",CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,https://dx.doi.org/10.1038/s41467-023-40064-9
sertindole,3590,,59,Human,Binding,AC50,=,140.0,6.85,-5,56,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"440,2",5,1,3,"4,63",O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
SERTRALINE,207985,,33,Human,Binding,AC50,=,10999.9,4.96,-1445,38,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"305,1",2,1,1,"5,18",CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,https://dx.doi.org/10.1038/s41467-023-40064-9
SIROLIMUS,161721,,39,Human,Binding,AC50,=,980.0,6.01,-,8,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"913,6",6,3,13,"6,18",CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,https://dx.doi.org/10.1038/s41467-023-40064-9
spiperone,3653,,40,Human,Binding,AC50,=,0.4,9.4,-5,69,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"395,2",6,1,4,"3,22",O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
SULCONAZOLE,15583,,40,Human,Binding,AC50,=,23999.9,4.62,-,18,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,396,6,0,3,"6,52",Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,https://dx.doi.org/10.1038/s41467-023-40064-9
SULTOPRIDE,98790,,31,Human,Binding,AC50,=,11.0,7.96,-1,7,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"354,2",7,1,5,"1,70",CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
SUNITINIB,194838,,50,Human,Binding,AC50,=,1148.9,5.94,-,37,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"398,2",7,3,3,"3,33",CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,https://dx.doi.org/10.1038/s41467-023-40064-9
TALIPEXOLE,98934,,37,Human,Binding,AC50,=,29000.1,4.54,-5,25,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"209,1",2,1,4,"1,31",C=CCN1CCc2nc(N)sc2CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
tamoxifen,3747,,45,Human,Binding,AC50,=,3200.0,5.5,-30,41,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"371,2",8,0,2,"6,00",CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,https://dx.doi.org/10.1038/s41467-023-40064-9
tamoxifen,3747,,45,Human,Binding,IC50,=,13885.0,4.86,-30,41,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"371,2",8,0,2,"6,00",CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,-
tamoxifen,3747,,45,Human,Binding,Ki,=,4628.0,5.33,-30,41,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"371,2",8,0,2,"6,00",CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,-
tamoxifen,3747,,45,Human,Binding,pKi,=,5.33,8.27,-30,41,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"371,2",8,0,2,"6,00",CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,-
tamsulosin,3749,,48,Human,Binding,AC50,=,100.0,7.0,-125,22,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"408,2",11,2,6,"2,34",CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
tegaserod,3773,,26,Human,Binding,AC50,=,3100.0,5.51,-38,39,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"301,2",7,3,3,"2,60",CCCCCN=C(N)N/N=C/c1c[nH]c2ccc(OC)cc12,https://dx.doi.org/10.1038/s41467-023-40064-9
terfenadine,3779,,53,Human,Binding,IC50,=,6167.0,5.21,-8,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"471,3",8,2,3,"6,45",CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,-
terfenadine,3779,,53,Human,Binding,Ki,=,2056.0,5.69,-8,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"471,3",8,2,3,"6,45",CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,-
terfenadine,3779,,53,Human,Binding,pKi,=,5.69,8.25,-8,32,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"471,3",8,2,3,"6,45",CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,-
terguride,3780,,25,Human,Binding,AC50,=,16.0,7.8,1,26,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"340,2",3,2,2,"2,93",CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,https://dx.doi.org/10.1038/s41467-023-40064-9
THIETHYLPERAZINE,28732,,28,Human,Binding,AC50,=,100.0,7.0,-1,18,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"399,2",6,0,5,"5,04",CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2,https://dx.doi.org/10.1038/s41467-023-40064-9
THIMEROSAL,189074,,0,Human,Binding,AC50,=,2500.0,5.6,-,15,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,-,-,-,-,-,-,https://dx.doi.org/10.1038/s41467-023-40064-9
THIOPROPERAZINE,204590,,44,Human,Binding,AC50,=,21.0,7.68,-9,21,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"446,2",6,0,6,"3,18",CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
thioridazine,3805,,44,Human,Binding,AC50,=,250.0,6.6,-3,64,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"370,2",4,0,4,"5,89",CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,https://dx.doi.org/10.1038/s41467-023-40064-9
thioridazine,3805,,44,Human,Binding,IC50,=,35.0,7.46,-3,64,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"370,2",4,0,4,"5,89",CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,-
thioridazine,3805,,44,Human,Binding,Ki,=,12.0,7.92,-3,64,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"370,2",4,0,4,"5,89",CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,-
THIOTEPA,206077,,58,Human,Binding,AC50,=,21000.0,4.68,-,14,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,189,3,0,1,"0,16",S=P(N1CC1)(N1CC1)N1CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
thiothixene,3806,,35,Human,Binding,AC50,=,2.7,8.57,5,32,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"443,2",5,0,5,"3,47",CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
TIAPRIDE,208386,,26,Human,Binding,AC50,=,300.0,6.52,-6,8,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"328,1",8,1,5,"1,17",CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
TIAPRIDE,208386,,26,Human,Binding,IC50,=,1232.0,5.91,-6,8,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"328,1",8,1,5,"1,17",CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC,-
TIAPRIDE,208386,,26,Human,Binding,Ki,=,411.0,6.39,-6,8,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"328,1",8,1,5,"1,17",CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC,-
TIOCONAZOLE,14425,,55,Human,Binding,AC50,=,12000.0,4.92,-,13,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,386,6,0,4,"5,86",Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1,https://dx.doi.org/10.1038/s41467-023-40064-9
trazodone,3853,,34,Human,Binding,AC50,=,3000.0,5.52,-23,46,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"371,2",5,0,6,"2,36",O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,https://dx.doi.org/10.1038/s41467-023-40064-9
trifluoperazine,3860,,43,Human,Binding,AC50,=,14.8,7.83,-2,44,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"407,2",4,0,4,"4,95",CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
TRIMETHOBENZAMIDE,14485,,39,Human,Binding,AC50,=,6900.0,5.16,-,2,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"388,2",10,1,6,"2,58",COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
URAPIDIL,98949,,48,Human,Binding,AC50,=,5900.0,5.23,-,16,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"387,2",7,1,8,"0,72",COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
VERALIPRIDE,78239,,45,Human,Binding,AC50,=,57.1,7.24,-,9,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"383,2",8,2,6,"0,73",C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
VERAPAMIL,206466,,47,Human,Binding,AC50,=,4400.0,5.36,-,21,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"454,3",13,0,6,"5,09",COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,https://dx.doi.org/10.1038/s41467-023-40064-9
xylometazoline,4107,,38,Human,Binding,AC50,=,15000.0,4.82,-,22,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"244,2",2,1,2,"3,15",Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,https://dx.doi.org/10.1038/s41467-023-40064-9
yohimbine,4127,,36,Human,Binding,AC50,=,188.9,6.72,-3715,53,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"354,2",1,2,4,"2,65",COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,https://dx.doi.org/10.1038/s41467-023-40064-9
yohimbine,4127,,36,Human,Binding,AC50,=,2545.6,5.59,-3715,53,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"354,2",1,2,4,"2,65",COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,https://dx.doi.org/10.1038/s41467-023-40064-9
yohimbine,4127,,36,Human,Binding,IC50,=,2060.0,5.69,-3715,53,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"354,2",1,2,4,"2,65",COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,-
yohimbine,4127,,36,Human,Binding,Ki,=,687.0,6.16,-3715,53,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),ChEMBL,"354,2",1,2,4,"2,65",COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,-
yohimbine,4127,,36,Human,Binding,pKi,=,6.16,8.21,-3715,53,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Drug Central,"354,2",1,2,4,"2,65",COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,-
ZIMELDINE,138516,,29,Human,Binding,AC50,=,23000.1,4.64,-,10,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"316,1",4,0,2,"3,84",CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1,https://dx.doi.org/10.1038/s41467-023-40064-9
ziprasidone,4143,,47,Human,Binding,AC50,=,26.0,7.58,-7,56,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"412,1",4,1,5,"3,81",O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,https://dx.doi.org/10.1038/s41467-023-40064-9
zotepine,4153,,44,Human,Binding,AC50,=,52.4,7.28,-9,60,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"331,1",4,0,3,"4,88",CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21,https://dx.doi.org/10.1038/s41467-023-40064-9
ZUCLOPENTHIXOL,194927,,32,Human,Binding,AC50,=,45.0,7.35,-,13,"Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay",ChEMBL,"400,1",5,1,4,"4,24",OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1,https://dx.doi.org/10.1038/s41467-023-40064-9
